BPTH Bio-Path Holdings Inc.

+0.17  (+1%)
Previous Close 15.02
Open 15
Price To Book 2.14
Market Cap 43008298
Shares 2,831,356
Volume 80,798
Short Ratio
Av. Daily Volume 996,778

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced December 29, 2017.
Chronic myelogenous leukemia (CML)
Phase 2 presentation at ASH December 2018. CR 4/17. Increased to 5/17 following updated analysis - March 6, 2019.
Prexigebersen - BP1001
Acute myeloid leukemia (AML)
Phase 1 trial to commence in 2020.
Pancreatic cancer

Latest News

  1. Edited Transcript of BPTH earnings conference call or presentation 16-May-19 12:30pm GMT
  2. Bio-Path: 1Q Earnings Snapshot
  3. Bio-Path Holdings Reports First Quarter 2019 Financial Results
  4. Bio-Path Holdings, Inc. to Host Earnings Call
  5. Easy Come, Easy Go: How Bio-Path Holdings (NASDAQ:BPTH) Shareholders Torched 97% Of Their Cash
  6. Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019
  7. Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
  8. How This Highly Rated Biotech Stock Added To Its Meteoric Run
  9. Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today
  10. Bio-Path's stock rockets after withdrawal of stock offering
  11. Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019
  12. Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons
  13. Bio-Path Holdings Reports Full Year 2018 Financial Results
  14. Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019
  15. Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
  16. Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock
  17. The Secret To Trading Stocks Like Bio-Path That Helped Me Quit My Desk Job And Make Thousands
  18. The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant